News, Short Squeeze, Breakout and More Instantly...
In this video from Motley Fool Live , recorded on Jan. 4, Corinne Cardina, bureau chief of healthcare and cannabis, and Fool.com contributor Brian Orelli discuss the upcoming decision by the Food and Drug Administration (FDA) over whether to approve aducanumab, Biogen 's (NASDAQ: ...
The study aims to identify digital biomarkers to help monitor cognitive performance and health including potentially detecting mild cognitive impairment, an early indicator of certain forms of dementia such as Alzheimer’s disease Cognitive health — the ability to...
The global Phase 4 RESPOND study will evaluate the efficacy and safety of SPINRAZA in patients with a suboptimal clinical response to Zolgensma Clinical and real-world experience have reported that some patients previously treated with Zolgensma have also been treated with SPINRAZA ...